While being much rarer than its KMT2A-AFF1 counterpart, KMT2A-AFF3 has been reported in several cases of high-risk infant and pediatric B-cell ALL (B-ALL), often presenting with the same aggressive clinical features, including chemotherapy resistance [7]. Here, AFF3 is linked to acute lymphoblastic leukemia.